Inactive Instrument

Admedus Ltd Share Price Australian S.E.

Equities

AU0000AHZDA7

Medical Equipment, Supplies & Distribution

End-of-day quote Australian S.E.
- AUD - Intraday chart for Admedus Ltd
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6M 4.02M 334M Sales 2025 * 6M 4.02M 334M Capitalization 377M 252M 21B
Net income 2024 * -79M -52.87M -4.4B Net income 2025 * -85M -56.88M -4.74B EV / Sales 2024 * 58.7 x
Net cash position 2024 * 25M 16.73M 1.39B Net cash position 2025 * 25M 16.73M 1.39B EV / Sales 2025 * 58.7 x
P/E ratio 2024 *
-5.27 x
P/E ratio 2025 *
-5.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.81%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 56 10/14/10
Director of Finance/CFO - 23/18/23
Chief Tech/Sci/R&D Officer - 06/21/06
Members of the board TitleAgeSince
Chairman 72 10/14/10
Director/Board Member - 31/18/31
Chief Executive Officer 56 10/14/10
More insiders
Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW